John Libbey Eurotext

European Journal of Dermatology

MENU

Real-life use of apremilast for the treatment of psoriasis in patients with oncological comorbidities: a retrospective descriptive multicentre study in France Volume 33, issue 1, January-February 2023

Figures


  • Figure 1

  • Figure 2

  • Figure 3

Tables

Authors
1 CHU Lille, service de dermatologie, F-59000 Lille, France
2 Association des dermatologues du Nord et du Pas-de-Calais (FEDERM 59-62), F-59000 Lille, France
3 Centre hospitalier de Valenciennes, service de dermatologie, F-59300 Valenciennes, France
4 Cabinet privé, F-59700 Marcq-en-Barœul, France
5 Centre hospitalier de Boulogne sur mer, service de dermatologie, F-62200 Boulogne-sur-Mer, France
6 Centre hospitalier de Douai, service de dermatologie, F-59507 Douai, France
7 Centre hospitalier de Dunkerque, service de dermatologie, F-59140 Dunkerque, France
8 U1286 Inserm INFINITE Institute for Translational Research in Inflammation, F-59000 Lille, France
* Reprints: Pauline Podevin

Psoriasis is a common inflammatory dermatosis with a strong impact on quality of life and associated comorbidities [1–6]. Treatment must be adapted to the severity of the disease and the patients’ comorbidities. Local treatments are the first line, as well as phototherapy. Then, in case of failure or more severe forms, conventional systemic treatments and biological therapies can be proposed. Apremilast (APR) is an oral phosphodiesterase inhibitor 4 [7], indicated for the treatment of moderate-to-severe [...]